A joint price negotiation bloc for middle-income countries, modelled on Beneluxa
Small European countries have started negotiating cancer drug prices together. A bloc of large middle-income countries would have far more bargaining power.
Beneluxa, the Nordic Pharmaceutical Forum and the Valletta Declaration group pool HTA and negotiation among European countries with modest results but proof of feasibility. Middle-income countries (Brazil, Mexico, Colombia, South Africa, Indonesia, Thailand, Egypt and others) negotiate alone and often pay list prices comparable to high-income countries for oncology drugs. The proposal is a formal negotiation bloc with a shared HTA secretariat, common evidence dossiers, and joint tenders or price agreements for new oncology medicines, backed by the PAHO Strategic Fund model for procurement.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Most of the world has almost no cancer care · Seven in ten cancer deaths happen in low- and middle-income countries, where radiotherapy, pathology, surgery and drugs are scarce.
Pages like this
not linked directly; found by shared links- IdeaBuy out the patent on a curative cancer drug and sell it at generic prices
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaGrant extra exclusivity only in exchange for binding low prices in poorer countries
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaTie WHO essential-medicines listing to a published tiered price and supply pledge
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaMedicines Patent Pool licences for every patented cancer drug on the WHO list
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaA Gavi-style pooled purchaser for radiotherapy equipment and service
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaPooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Shares Prices and value, Most of the world has almost no cancer care.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Prices and value, Most of the world has almost no cancer care.